Literature DB >> 8151790

Second-site long terminal repeat (LTR) revertants of replication-defective human immunodeficiency virus: effects of revertant TATA box motifs on virus infectivity, LTR-directed expression, in vitro RNA synthesis, and binding of basal transcription factors TFIID and TFIIA.

F Kashanchi1, R Shibata, E K Ross, J N Brady, M A Martin.   

Abstract

Second-site revertants from replication-incompetent molecular clones of human immunodeficiency virus (HIV) contain base substitutions adjacent to the TATA motif. The altered TATA box motifs were analyzed for their effect(s) on virus infectivity, long terminal repeat (LTR)-directed expression in transient transfection assays, in vitro RNA synthesis, and assembly of the TFIID-TFIIA preinitiation complex. The revertant TATA boxes accelerated the kinetics of HIV replication when present in the context of an LTR containing a Sp1 mutation (deletion or site specific); no effect was observed on the infectivity of wild-type HIV. In chloramphenicol acetyltransferase assays and in vitro transcription systems, the altered TATA box motifs led to elevated basal levels of RNA synthesis from NF-kappa B- and Sp1-mutagenized and wild-type templates, respectively, but did not increase responsiveness to Tat transactivation. The revertant TATA boxes accelerated the binding of TFIID and TFIIA to the LTR and stabilized their association with the promoter. The revertants did not assemble a more-processive elongation complex. These results suggest that in the context of an impaired enhancer/promoter (viz., three mutated Sp1 elements), a series of HIV revertants emerge which contain LTR alterations that significantly augment basal RNA synthesis. The TATA motif revertants are capable of rescuing the enhancer/promoter defect and sustain virus infectivity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8151790      PMCID: PMC236820     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  51 in total

1.  The location of cis-acting regulatory sequences in the human T cell lymphotropic virus type III (HTLV-III/LAV) long terminal repeat.

Authors:  C A Rosen; J G Sodroski; W A Haseltine
Journal:  Cell       Date:  1985-07       Impact factor: 41.582

2.  Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay.

Authors:  S Harada; Y Koyanagi; N Yamamoto
Journal:  Science       Date:  1985-08-09       Impact factor: 47.728

3.  Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.

Authors:  A Adachi; H E Gendelman; S Koenig; T Folks; R Willey; A Rabson; M A Martin
Journal:  J Virol       Date:  1986-08       Impact factor: 5.103

4.  Expression and characterization of the trans-activator of HTLV-III/LAV virus.

Authors:  C M Wright; B K Felber; H Paskalis; G N Pavlakis
Journal:  Science       Date:  1986-11-21       Impact factor: 47.728

5.  The role of T3 surface molecules in the activation of human T cells: a two-stimulus requirement for IL 2 production reflects events occurring at a pre-translational level.

Authors:  A Weiss; R L Wiskocil; J D Stobo
Journal:  J Immunol       Date:  1984-07       Impact factor: 5.422

6.  DNA-dependent transcription of adenovirus genes in a soluble whole-cell extract.

Authors:  J L Manley; A Fire; A Cano; P A Sharp; M L Gefter
Journal:  Proc Natl Acad Sci U S A       Date:  1980-07       Impact factor: 11.205

7.  Characterization of a continuous T-cell line susceptible to the cytopathic effects of the acquired immunodeficiency syndrome (AIDS)-associated retrovirus.

Authors:  T Folks; S Benn; A Rabson; T Theodore; M D Hoggan; M Martin; M Lightfoote; K Sell
Journal:  Proc Natl Acad Sci U S A       Date:  1985-07       Impact factor: 11.205

8.  Activation of the AIDS retrovirus promoter by the cellular transcription factor, Sp1.

Authors:  K A Jones; J T Kadonaga; P A Luciw; R Tjian
Journal:  Science       Date:  1986-05-09       Impact factor: 47.728

9.  The human immunodeficiency virus type 1 long terminal repeat specifies two different transcription complexes, only one of which is regulated by Tat.

Authors:  X Lu; T M Welsh; B M Peterlin
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

10.  Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS.

Authors:  M Popovic; M G Sarngadharan; E Read; R C Gallo
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

View more
  21 in total

1.  Transcriptional gene silencing of HIV-1 through promoter targeted RNA is highly specific.

Authors:  Kazuo Suzuki; Takaomi Ishida; Makoto Yamagishi; Chantelle Ahlenstiel; Sanjay Swaminathan; Katharine Marks; Daniel Murray; Erin M McCartney; Michael R Beard; Marina Alexander; Damian F J Purcell; David A Cooper; Toshiki Watanabe; Anthony D Kelleher
Journal:  RNA Biol       Date:  2011-11-01       Impact factor: 4.652

2.  Use of ATP analogs to inhibit HIV-1 transcription.

Authors:  Aarthi Narayanan; Gavin Sampey; Rachel Van Duyne; Irene Guendel; Kylene Kehn-Hall; Jessica Roman; Robert Currer; Hervé Galons; Nassima Oumata; Benoît Joseph; Laurent Meijer; Massimo Caputi; Sergei Nekhai; Fatah Kashanchi
Journal:  Virology       Date:  2012-07-06       Impact factor: 3.616

3.  Anti HIV-1 virucidal activity of polyamide nucleic acid-membrane transducing peptide conjugates targeted to primer binding site of HIV-1 genome.

Authors:  Snehlata Tripathi; Binay Chaubey; Beverly E Barton; Virendra N Pandey
Journal:  Virology       Date:  2007-02-21       Impact factor: 3.616

4.  Destabilization of tRNA3(Lys) from the primer-binding site of HIV-1 genome by anti-A loop polyamide nucleotide analog.

Authors:  N Kaushik; T T Talele; R Monel; P Palumbo; V N Pandey
Journal:  Nucleic Acids Res       Date:  2001-12-15       Impact factor: 16.971

5.  Sequential steps in Tat trans-activation of HIV-1 mediated through cellular DNA, RNA, and protein binding factors.

Authors:  A Gatignol; M Duarte; L Daviet; Y N Chang; K T Jeang
Journal:  Gene Expr       Date:  1996

6.  Cell cycle-regulated transcription by the human immunodeficiency virus type 1 Tat transactivator.

Authors:  F Kashanchi; E T Agbottah; C A Pise-Masison; R Mahieux; J Duvall; A Kumar; J N Brady
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

7.  Interaction of human immunodeficiency virus type 1 Tat with a unique site of TFIID inhibits negative cofactor Dr1 and stabilizes the TFIID-TFIIA complex.

Authors:  F Kashanchi; S N Khleif; J F Duvall; M R Sadaie; M F Radonovich; M Cho; M A Martin; S Y Chen; R Weinmann; J N Brady
Journal:  J Virol       Date:  1996-08       Impact factor: 5.103

8.  Effect of mimetic CDK9 inhibitors on HIV-1-activated transcription.

Authors:  Rachel Van Duyne; Irene Guendel; Elizabeth Jaworski; Gavin Sampey; Zachary Klase; Hao Chen; Chen Zeng; Dmytro Kovalskyy; Mahmoud H El Kouni; Benjamin Lepene; Alexis Patanarut; Sergei Nekhai; David H Price; Fatah Kashanchi
Journal:  J Mol Biol       Date:  2012-12-13       Impact factor: 5.469

9.  Acetylated Tat regulates human immunodeficiency virus type 1 splicing through its interaction with the splicing regulator p32.

Authors:  Reem Berro; Kylene Kehn; Cynthia de la Fuente; Anne Pumfery; Richard Adair; John Wade; Anamaris M Colberg-Poley; John Hiscott; Fatah Kashanchi
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

10.  Efficient transcription and replication of simian immunodeficiency virus in the absence of NF-kappaB and Sp1 binding elements.

Authors:  P O Ilyinskii; R C Desrosiers
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.